Richter’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Richter’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies https://clinicaltrials.eu/trial/evaluation-of-safety-and-efficacy-of-zilovertamab-vedotin-and-nemtabrutinib-in-aggressive-and-indolent-b-cell-malignancies/ Thu, 30 Apr 2026 13:08:49 +0000 https://clinicaltrials.eu/trial/evaluation-of-safety-and-efficacy-of-zilovertamab-vedotin-and-nemtabrutinib-in-aggressive-and-indolent-b-cell-malignancies/ This clinical trial is focused on studying certain types of blood cancers known as B-cell malignancies. These include aggressive forms like mantle cell lymphoma and Richter’s syndrome, as well as more slow-growing types such as chronic lymphocytic leukemia and follicular lymphoma. The study will test the safety and effectiveness of a medication called Zilovertamab Vedotin, both on its own and in combination with another drug named Nemtabrutinib.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

]]> Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ This clinical trial is studying treatments for B-cell malignancies that have returned or not responded to previous treatments. The study will test different combinations of medications, including BGB-16673, zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. The purpose is to find safe and effective treatment combinations for patients whose cancer has come back or did not respond to earlier treatments.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

]]> Study on the Effects of Acalabrutinib in Patients with Chronic Lymphocytic Leukemia, Richter’s Syndrome, or Prolymphocytic Leukemia https://clinicaltrials.eu/trial/study-on-the-effects-of-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia-richters-syndrome-or-prolymphocytic-leukemia/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia-richters-syndrome-or-prolymphocytic-leukemia/ This clinical trial is focused on studying the effects of a medication called acalabrutinib, also known by its code name ACP-196. The trial is designed to explore its use in treating certain types of blood cancers, specifically Chronic Lymphocytic Leukemia (CLL), Richter’s Syndrome, and Prolymphocytic Leukemia. These are conditions where the body produces abnormal white blood cells, which can affect the immune system and overall health. The medication is provided in two forms: film-coated tablets and hard capsules, both taken orally.

The purpose of the study is to determine the safety and appropriate dosage of acalabrutinib for patients with these conditions. Participants in the trial will receive the medication in increasing doses to find the most effective and safe amount. The study will also look at how the body processes the medication and its effects on the disease. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will be monitored closely to observe how their bodies respond to the treatment. This includes regular check-ups and tests to ensure their safety and to gather information on the medication’s impact. The trial aims to provide valuable insights into the potential benefits of acalabrutinib for treating these specific types of leukemia and related conditions.

]]> Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-venetoclax-atezolizumab-and-obinutuzumab-for-patients-with-richter-syndrome-from-chronic-lymphocytic-leukemia/ Wed, 29 Apr 2026 14:58:22 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-venetoclax-atezolizumab-and-obinutuzumab-for-patients-with-richter-syndrome-from-chronic-lymphocytic-leukemia/ This clinical trial is focused on studying a condition known as Richter syndrome, which is a transformation of chronic lymphocytic leukemia (CLL) into a more aggressive form of lymphoma. The trial is testing a combination of three treatments: venetoclax, atezolizumab, and obinutuzumab. Venetoclax is a medication that comes in the form of a film-coated tablet and is taken orally. Atezolizumab and obinutuzumab are both monoclonal antibodies, which are proteins designed to target specific cells, and are administered through an intravenous infusion, meaning they are given directly into a vein.

The purpose of this study is to evaluate the safety and effectiveness of this combination of treatments in patients with Richter syndrome. Participants in the study will receive these medications over a period of time, and their response to the treatment will be monitored. The study aims to see if the combination can achieve a significant response rate, which means a reduction in the size or extent of the cancer. The study will also look at how long the response lasts, the time it takes for the disease to progress, and the overall survival of the participants.

Throughout the study, the occurrence of any side effects or serious adverse events will be closely monitored. This includes any significant changes in laboratory test results and how well participants tolerate the doses of the medications. The study will provide valuable information on the potential benefits and risks of using venetoclax, atezolizumab, and obinutuzumab together for treating Richter syndrome in CLL patients.

]]> Study of Mosunetuzumab and Drug Combination for Untreated Patients with Richter’s Syndrome https://clinicaltrials.eu/trial/study-of-mosunetuzumab-and-drug-combination-for-untreated-patients-with-richters-syndrome/ Wed, 29 Apr 2026 14:29:55 +0000 https://clinicaltrials.eu/trial/study-of-mosunetuzumab-and-drug-combination-for-untreated-patients-with-richters-syndrome/ This clinical trial is focused on studying a condition known as Richter’s syndrome, which is a transformation of chronic lymphocytic leukemia into a more aggressive form of lymphoma. The study will explore the effectiveness of a treatment combination called M-CHOP, which includes the medications mosunetuzumab, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide monohydrate, and prednisone. These medications are administered to patients who have not previously received treatment for this condition.

The purpose of the study is to evaluate how well this combination works in treating patients with Richter’s syndrome. Participants will receive the treatment over a period of time, with regular monitoring to assess their response. The study will involve a series of treatment cycles, each lasting a few weeks, during which the medications will be given intravenously, except for prednisone, which is taken orally. The study will also include a comparison with a placebo to determine the effectiveness of the treatment.

Throughout the study, participants will be closely monitored for any side effects and their overall health will be assessed regularly. The study aims to provide valuable information on the potential benefits of the M-CHOP treatment combination for patients with Richter’s syndrome, helping to improve future treatment options for this condition.

]]> Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT) https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-richter-transformation-rt/ Wed, 29 Apr 2026 14:24:50 +0000 https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-richter-transformation-rt/ This clinical trial is focused on studying a rare type of cancer called Richter Transformation, which occurs when chronic lymphocytic leukemia (CLL) transforms into a more aggressive form known as diffuse large B-cell lymphoma (DLBCL). The study is investigating the effectiveness and safety of a treatment called brexucabtagene autoleucel, a type of cell therapy that uses genetically modified T cells to target and destroy cancer cells. This treatment is specifically designed for adults who have experienced a relapse or whose disease has not responded to previous treatments.

The purpose of the study is to evaluate how well brexucabtagene autoleucel works in treating patients with Richter Transformation. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will monitor the participants’ response to the treatment, including whether the cancer shrinks or disappears, and how long the response lasts. The study will also assess the overall survival of participants and the time it takes for the disease to progress or for the next treatment to be needed.

In addition to brexucabtagene autoleucel, the study may involve other medications to support the treatment process. These include carboplatin, mesna, ifosfamide, vincristine, etoposide, gemcitabine, oxaliplatin, methylprednisolone, rituximab, alpelisib, and ibrutinib. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using brexucabtagene autoleucel for treating this challenging condition.

]]> Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter’s Syndrome Patients https://clinicaltrials.eu/trial/study-of-glofitamab-with-rituximab-or-obinutuzumab-and-drug-combination-for-untreated-richters-syndrome-patients/ Wed, 29 Apr 2026 14:23:24 +0000 https://clinicaltrials.eu/trial/study-of-glofitamab-with-rituximab-or-obinutuzumab-and-drug-combination-for-untreated-richters-syndrome-patients/ This clinical trial is focused on studying a condition known as Richter’s syndrome, which occurs when chronic lymphocytic leukemia (CLL) transforms into a more aggressive form of cancer called diffuse large B-cell lymphoma (DLBCL). The study aims to evaluate the effectiveness of a new treatment combination for patients who have not previously received treatment for Richter’s syndrome. The treatment involves a combination of medications, including Glofitamab, a bispecific antibody that targets specific proteins on cancer cells, in combination with either Rituximab or Obinutuzumab, along with a chemotherapy regimen known as CHOP. CHOP includes the drugs Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

The purpose of the study is to determine how well this combination of treatments works in reducing the cancer in patients with Richter’s syndrome. Participants in the study will receive up to six cycles of the treatment, which involves receiving the medications through an intravenous infusion, meaning the drugs are delivered directly into the bloodstream through a vein. The study will monitor the response of the cancer to the treatment over time, as well as any side effects that may occur.

Throughout the study, participants will undergo regular assessments to track the progress of the treatment. These assessments may include imaging tests and other evaluations to measure the size and activity of the cancer. The study will also look at how long the treatment effects last and the overall survival of the participants. The goal is to gather information that could lead to improved treatment options for patients with Richter’s syndrome in the future.

]]>